Enteric Immune–Neural Communication in Gastrointestinal Health

Abstract

The enteric immune–neural axis is a sophisticated communication network central to gastrointestinal (GI) health, integrating the enteric nervous system (ENS) with mucosal immunity to orchestrate motility, secretion, and immune responses. Recent advances have elucidated the molecular dialogues between immune cells and enteric neurons, highlighting their pivotal roles in maintaining intestinal homeostasis and contributing to disease pathogenesis. This review synthesizes current evidence on the clinical and physiological significance of immune–neural crosstalk, delineating the mechanisms, disease relevance, diagnostic approaches, treatment modalities, and emerging therapeutic strategies with a focus on implications for clinical practice and future research directions.

Introduction

The GI tract harbors one of the body's most intricate neuroimmune interfaces, where the ENS, often referred to as the "second brain", interacts dynamically with immune cells populating the gut mucosa. This bidirectional communication is fundamental to GI function, modulating not only digestion and absorption but also host defense and inflammatory responses. Disruption of this finely tuned network underpins a range of GI disorders, from functional GI syndromes to inflammatory bowel disease (IBD) and infection. Understanding the physiological and pathological aspects of enteric immune–neural communication is vital for clinicians seeking to optimize the management of GI diseases and leverage novel therapeutic targets.

Epidemiology / Disease Burden

Disorders implicating enteric immune–neural dysregulation, such as IBD, irritable bowel syndrome (IBS), and post-infectious GI syndromes, affect millions globally, imposing a significant burden on healthcare systems and patients quality of life. For instance, IBS has a worldwide prevalence of approximately 10–15%, while IBD incidence continues to rise in both developed and developing regions. These conditions are frequently chronic, relapsing, and associated with substantial morbidity, underscoring the importance of understanding underlying mechanistic pathways for improved diagnosis and management.

Pathophysiology

The enteric immune–neural axis comprises complex interactions between the ENS, including intrinsic primary afferent neurons, interneurons, and motor neurons, and immune cells such as macrophages, dendritic cells, mast cells, and T lymphocytes. Neurotransmitters (acetylcholine, vasoactive intestinal peptide, serotonin) and neuropeptides modulate immune cell function, while cytokines, chemokines, and mediators from immune cells reciprocally influence neuronal activity. Key mechanisms include:

• Mast cell–nerve axis: Mast cell degranulation releases histamine and tryptase, sensitizing enteric neurons and contributing to visceral hypersensitivity.
• Macrophage–ENS interaction: Muscularis macrophages regulate gut motility through direct communication with enteric neurons via bone morphogenetic protein signaling.
• Gut–brain axis: Vagal and spinal afferents transmit immune signals to the CNS, influencing GI physiology and systemic immune responses.

Dysregulation leads to altered motility, secretion, permeability, and aberrant immune activation, as seen in IBD, IBS, and enteric infections.

Risk Factors

Risk factors for enteric immune–neural dysfunction include genetic predisposition (NOD2, IL23R polymorphisms in IBD), early-life infectious exposures, antibiotic use, psychosocial stress, and dietary factors. Environmental triggers can incite aberrant immune responses or alter ENS function, priming the gut for chronic inflammation or dysmotility. The gut microbiota also modulates immune–neural interactions, with dysbiosis implicated in both immune activation and ENS signaling changes.

Clinical Features

Clinical manifestations of immune–neural dysregulation are protean, reflecting the diverse functions of the ENS and gut immune system. Common features include abdominal pain, altered bowel habits (diarrhea, constipation), bloating, and urgency. In IBD, immune–neural disruption contributes to persistent inflammation, pain, and motility disturbances, while in IBS, visceral hypersensitivity and dysmotility predominate. Extra-intestinal symptoms such as fatigue and mood disorders may arise via gut–brain axis signaling.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory, endoscopic, and histopathological assessment. Biomarkers of immune activation (fecal calprotectin, C-reactive protein) aid in differentiating inflammatory from functional disorders. Advanced techniques, including confocal laser endomicroscopy and molecular imaging, have enhanced the ability to visualize neuroimmune interactions in vivo. Emerging biomarkers reflecting neuropeptide levels or neuronal injury may further refine diagnostic accuracy in the future.

Treatment & Management

Therapeutic strategies target both neural and immune components. In IBD, immunosuppressive agents (corticosteroids, biologics targeting TNF-α, IL-12/23) remain the cornerstone. For IBS, neuromodulators (tricyclic antidepressants, selective serotonin reuptake inhibitors) and agents modulating gut motility or secretion (antispasmodics, secretagogues) are frequently employed. Non-pharmacologic interventions, such as dietary modification (low FODMAP diet), stress reduction, and gut-directed hypnotherapy, address both neuroimmune and psychosocial contributors. A multidisciplinary approach, integrating gastroenterology, psychology, and nutrition, is often warranted for optimal outcomes.

Recent Advances / Emerging Therapies

Recent advances have illuminated novel therapeutic targets within the immune–neural axis. Monoclonal antibodies against integrins (vedolizumab) and Janus kinase inhibitors (tofacitinib) offer targeted immune modulation in IBD. Neuromodulatory strategies, including peripherally acting opioid receptor antagonists and 5-HT4 agonists, have shown efficacy in functional GI disorders. The role of the microbiome is increasingly recognized, with fecal microbiota transplantation and probiotics being explored for their impact on neuroimmune signaling. Optogenetic and chemogenetic modulation of enteric neurons represents a frontier in precision therapy, while advances in mucosal immunology may yield biomarkers for personalized treatment approaches.

Guideline Recommendations

Current guidelines emphasize individualized, evidence-based management tailored to disease severity and predominant symptoms. For IBD, early use of biologic therapy is recommended in high-risk patients, with regular assessment of response and adverse effects. In IBS, a stepwise approach incorporating lifestyle, dietary, pharmacologic, and psychological therapies is advocated. The integration of neuroimmune-targeted therapies is anticipated as further research elucidates their efficacy and safety profiles. Multidisciplinary care and patient education are essential in optimizing adherence and clinical outcomes.

Conclusion

The enteric immune–neural axis is fundamental to GI health, with its disruption contributing to a spectrum of diseases characterized by significant morbidity. Advances in understanding the molecular and cellular mechanisms of neuroimmune communication have opened avenues for novel diagnostic and therapeutic strategies. Ongoing research into the interplay between the ENS, immune system, and microbiota will further inform clinical practice, offering the promise of personalized medicine and improved outcomes in GI disorders. Enhanced awareness and integration of neuroimmune principles are essential for healthcare professionals managing complex GI diseases in the modern era.